Effectiveness and Safety of Topical Hyaluronic Acid of Different Molecular Weights in Xerotic Skin Treatment
Launched by INDONESIA UNIVERSITY · Dec 10, 2023
Trial Information
Current as of October 02, 2025
Completed
Keywords
ClinConnect Summary
This clinical trial is conducted to compare the effectiveness and safety between moisturizers containing 0,1% low molecular weight hyaluronic acid, 0,1% high molecular weight hyaluronic acid, and its vehicle on skin hydration of elderly with xerotic skin. It is designed to answer following questions:
1. Is the skin capacitance in the elderly after using moisturizers containing low molecular weight hyaluronic acid higher than high molecular weight hyaluronate acid and vehicle?
2. Is the transepidermal water loss in the elderly after using moisturizers containing high molecular weight hyalur...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Female or male diagnosed with xerotic skin
- • 60-80 years old
- • Willing to participate in clinical trial and sign informed consent
- Exclusion Criteria:
- • History of hypersensitivity to moisturizer
- • Dermatitis or any dermatosis on intervention area in the leg
- • Score of erythema and crack more than 2, based on SRRC scoring
About Indonesia University
Indonesia University is a leading academic institution dedicated to advancing healthcare through rigorous clinical research. As a trial sponsor, the university leverages its extensive expertise in medical science and collaboration with top-tier researchers to design and implement innovative clinical trials. Committed to ethical standards and patient safety, Indonesia University aims to contribute to the global body of knowledge in medicine, enhance therapeutic options, and improve health outcomes for diverse populations. Through its comprehensive approach, the university fosters an environment of scientific inquiry and collaboration, driving progress in clinical research and education.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jakarta, Dki Jakarta, Indonesia
Patients applied
Trial Officials
Parikesit Muhammad, MD
Principal Investigator
Faculty of Medicine, University of Indonesia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported